NewEdge Wealth LLC Grows Stock Position in Gilead Sciences, Inc. $GILD

NewEdge Wealth LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 619,690 shares of the biopharmaceutical company’s stock after buying an additional 17,284 shares during the quarter. Gilead Sciences comprises 1.1% of NewEdge Wealth LLC’s holdings, making the stock its 13th largest position. NewEdge Wealth LLC’s holdings in Gilead Sciences were worth $75,962,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GoalVest Advisory LLC grew its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new position in Gilead Sciences during the 3rd quarter valued at $26,000. Putney Financial Group LLC increased its position in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences during the second quarter worth about $30,000. Finally, MTM Investment Management LLC grew its stake in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on GILD to $170 and maintained a Buy rating — this adds upside perception (~11% above recent price) and supports bullish analyst-driven flows. Rothschild PT Raise
• Positive Sentiment: News highlighting Gilead’s HIV franchise progress and a Yescarta label shift is reframing the investment thesis toward durable HIV revenue plus potential CAR-T positioning — supportive for medium-term growth expectations. HIV & Yescarta Article
• Neutral Sentiment: Maxim Group’s Michael Okunewitch reiterated a Hold rating, noting strong HIV growth may be largely priced in and diversification still limited — a cautious tone that tempers upside. TipRanks / Hold Rating
• Neutral Sentiment: Benzinga’s retrospective on 5‑year returns (what $1,000 then would be worth today) is informational for retail investors but unlikely to move price materially by itself. Benzinga Performance Piece
• Neutral Sentiment: Analyst Q&A coverage from Gilead’s Q4 earnings call highlights issues analysts want answered (pipeline timing, margins, guidance drivers). Useful context for investors but mixed in directional impact. Q4 Earnings Call Questions
• Negative Sentiment: Insider selling: CFO Andrew D. Dickinson sold 3,000 shares at ~$$154.43 (SEC filing). Large or leadership insider sales can pressure sentiment even when scheduled/known. CFO Form 4
• Negative Sentiment: Significant insider sale by Johanna Mercier: 28,000 shares sold at ~$$154.44 (18.9% reduction in her holding) — a large single insider transaction that may weigh on investor confidence. Mercier Form 4

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. This represents a 16.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 319,891 shares of company stock valued at $45,091,556 in the last 90 days. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GILD shares. Cantor Fitzgerald lifted their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. HSBC lifted their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. BMO Capital Markets upped their target price on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. Finally, Rothschild & Co Redburn upped their price objective on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $152.96.

Gilead Sciences Stock Performance

Shares of GILD opened at $152.74 on Thursday. The company has a market capitalization of $189.50 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. The company’s fifty day moving average price is $132.29 and its 200 day moving average price is $123.18. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is presently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.